Phosphorylated 4E binding protein 1: A hallmark of cell signaling that correlates with survival in ovarian cancer

被引:147
作者
Castellvi, Josep
Garcia, Angel
Rojo, Federico
Ruiz-Marcellan, Carmen
Gil, Antonio
Baselga, Jose
Ramon y Cajal, Santiago
机构
[1] Vall Hebron Univ Hosp, Dept Pathol, Barcelona 08035, Spain
[2] Vall Hebron Univ Hosp, Dept Gynecol, Barcelona 08035, Spain
[3] Vall Hebron Univ Hosp, Dept Oncol, Barcelona 08035, Spain
关键词
cell signaling; ovarian neoplasms; prognostic factors; 4E binding protein 1;
D O I
10.1002/cncr.22195
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Growth factor receptors and cell signaling factors play a crucial role in human carcinomas and have been studied in ovarian tumors with varying results. Cell signaling involves multiple pathways and a myriad of factors that can be mutated or amplified. Cell signaling is driven through the mammalian target of rapamycin (mTOR) and extracellular regulated kinase (ERK) pathways and by some downstream molecules, such as 4E binding protein 1 (4EBP1), eukaryotic initiation factor 4E, and p70 ribosomal protein S6 kinase (p70S6K). The objectives of this study were to analyze the real role that these pathways play in ovarian cancer, to correlate them with clinicopathologic characteristics, and to identify the factors that transmit individual proliferation signals and are associated with pathologic grade and prognosis, regardless specific oncogenic alterations upstream. METHODS. One hundred twenty-nine ovarian epithelial tumors were studied, including 20 serous cystadenomas, 7 mucinous cystadenomas, I I serous borderline tumors, 16 mucinous borderline tumors, 29 serous carcinomas, 16 endometrioid carcinomas, 15 clear cell carcinomas, and 15 mucinous carcinomas. Tissue microarrays were constructed, and immunohistochemistry for the receptors epidermal growth factor receptor (EGFR) and c-erb-B2 was performed and with phosphorylated antibodies for protein kinase B (AKT), 4EBP1, p70S6K, S6, and ERK. RESULTS. Among 129 ovarian neoplasms, 17.8% were positive for c-erb-B2, 9.3% were positive for EGFR, 47.3% were positive for phosphorylated AKT (p-AKT), 58.9% were positive for p-ERK, 41.1% were positive for p-4EBP1, 26.4% were positive for p70S6K, and 15.5% were positive for p-S6. Although EGFR, p-AKT, and p-ERK expression did not differ between benign, borderline, or malignant tumors, c-erb-B2, p-4EBP1, p-p70S6K, and p-S6 were expressed significantly more often in malignant tumors. Only p-4EBP1 expression demonstrated prognostic significance (P =.005), and only surgical stage and p-4EBP1 expression had statistical significance in the multivariate analysis. CONCLUSIONS. in patients with ovarian carcinoma, significant expression of p-4EBP1 was associated with high-grade tumors and a poor prognosis, regardless other oncogenic alterations upstream. This finding supports the study of this factor as a hallmark or pivotal factor in cell signaling in ovarian carcinoma that may crucial in the transmission of the proliferation cell signal and may reflect the real oncogenic role of this pathway in ovarian tumors. (c) 2006 American Cancer Society.
引用
收藏
页码:1801 / 1811
页数:11
相关论文
共 47 条
[1]   AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth [J].
Altomare, DA ;
Wang, HQ ;
Skele, KL ;
De Rienzo, A ;
Klein-Szanto, AJ ;
Godwin, AK ;
Testa, JR .
ONCOGENE, 2004, 23 (34) :5853-5857
[2]   Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells [J].
Avdulov, S ;
Li, S ;
Michalek, V ;
Burrichter, D ;
Peterson, M ;
Perlman, DM ;
Manivel, JC ;
Sonenberg, N ;
Yee, D ;
Bitterman, PB ;
Polunovsky, VA .
CANCER CELL, 2004, 5 (06) :553-563
[3]   EPIDERMAL GROWTH-FACTOR RECEPTOR EXPRESSION IN NORMAL OVARIAN EPITHELIUM AND OVARIAN-CANCER .1. CORRELATION OF RECEPTOR EXPRESSION WITH PROGNOSTIC FACTORS IN PATIENTS WITH OVARIAN-CANCER [J].
BERCHUCK, A ;
RODRIGUEZ, GC ;
KAMEL, A ;
DODGE, RK ;
SOPER, JT ;
CLARKEPEARSON, DL ;
BAST, RC .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1991, 164 (02) :669-674
[4]   OVEREXPRESSION OF HER-2 NEU IN ENDOMETRIAL CANCER IS ASSOCIATED WITH ADVANCED STAGE DISEASE [J].
BERCHUCK, A ;
RODRIGUEZ, G ;
KINNEY, RB ;
SOPER, JT ;
DODGE, RK ;
CLARKEPEARSON, DL ;
BAST, RC .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1991, 164 (01) :15-21
[5]   The TOR pathway: A target for cancer therapy [J].
Bjornsti, MA ;
Houghton, PJ .
NATURE REVIEWS CANCER, 2004, 4 (05) :335-348
[6]   HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma:: a multicenter study of the GINECO group [J].
Camilleri-Broët, S ;
Hardy-Bessard, AC ;
Le Tourneau, A ;
Paraiso, D ;
Levrel, O ;
Leduc, B ;
Bain, S ;
Orfeuvre, H ;
Audouin, J ;
Pujade-Lauraine, E .
ANNALS OF ONCOLOGY, 2004, 15 (01) :104-112
[7]   Alternative phospholipase D/mTOR survival signal in human breast cancer cells [J].
Chen, YH ;
Rodrik, V ;
Foster, DA .
ONCOGENE, 2005, 24 (04) :672-679
[8]   Regulation of the phosphorylation and integrity of protein synthesis initiation factor eIF4GI and the translational repressor 4E-BP1 by p53 [J].
Constantinou, C ;
Clemens, MJ .
ONCOGENE, 2005, 24 (30) :4839-4850
[9]   Prognostic significance of activated Akt expression in melanoma: A clinicopathologic study of 292 cases [J].
Dai, DL ;
Martinka, M ;
Li, G .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (07) :1473-1482
[10]   Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage [J].
David, O ;
Jett, J ;
LeBeau, H ;
Dy, G ;
Hughes, J ;
Friedman, M ;
Brody, AR .
CLINICAL CANCER RESEARCH, 2004, 10 (20) :6865-6871